PTC Therapeutics (NASDAQ:PTCT) Cut to Sell at Citigroup

Citigroup downgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a neutral rating to a sell rating in a research note issued to investors on Friday morning, MarketBeat Ratings reports. Citigroup currently has $17.00 target price on the biopharmaceutical company’s stock, down from their previous target price of $29.00. Several other equities analysts have […]

Leave a Reply

Your email address will not be published.

Previous post Ribbon Communications (NASDAQ:RBBN) Stock Rating Lowered by
Next post O’Reilly Automotive (NASDAQ:ORLY) Price Target Increased to $1,080.00 by Analysts at Truist Financial